S. Hawser

发表

Comparison of a 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenylamino)Carbonyl]-2H-Tetrazolium Hydroxide (XTT) Colorimetric Method with the Standardized National Committee for Clinical Laboratory Standards Method of Testing Clinical Yeast Isolates for Susceptibility to Antifungal Agents

M. Ghannoum, S. Hawser, H. Norris, 1998, Journal of Clinical Microbiology.

Utility of 2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium Hydroxide (XTT) and Minimum Effective Concentration Assays in the Determination of Antifungal Susceptibility of Aspergillus fumigatus to the Lipopeptide Class of Compounds

M. Ghannoum, S. Hawser, C. Jessup, 2001, Journal of Clinical Microbiology.

Surveillance programmes and antibiotic resistance: worldwide and regional monitoring of antibiotic resistance trends.

S. Hawser, 2012, Handbook of experimental pharmacology.

A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011

I. Morrissey, M. Hackel, S. Hawser, 2013, Pharmaceuticals.

Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010.

L. Nicolle, M. Hackel, D. Hoban, 2012, Diagnostic microbiology and infectious disease.

Low frequency of ertapenem-resistant intra-abdominal isolates of Escherichia coli from Latin America: susceptibility, ESBL-occurrence, and molecular characterisation (SMART 2008–2009)

M. Hackel, F. Rossi, D. Hoban, 2012, Journal of chemotherapy.

Biofilm formation by Candida species on the surface of catheter materials in vitro

L. J. Douglas, S. Hawser, S P Hawser, 1994, Infection and immunity.

Resistance of Candida albicans biofilms to antifungal agents in vitro

L. J. Douglas, S. Hawser, L. Douglas, 1995, Antimicrobial agents and chemotherapy.

The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.

C. Charrier, S. Hawser, David B. Huang, 2019, Journal of medical microbiology.

Antistreptococcal Activity of AR-709 Compared to That of Other Agents

S. Lociuro, S. Hawser, L. Ednie, 2008, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011.

D. Hoban, S. Hawser, S. Bouchillon, 2013, Clinical therapeutics.

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017

I. Morrissey, M. Bassetti, J. Karlowsky, 2019, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017

I. Morrissey, M. Bassetti, J. Karlowsky, 2019, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections

S. Magnet, S. Hawser, David B. Huang, 2019, Antimicrobial Agents and Chemotherapy.

Toxicity of blooms of the cyanobacterium Trichodesmium to zooplankton

M. Roman, G. Codd, J. O'Neil, 1992, Journal of Applied Phycology.

A neurotoxic factor associated with the bloom-forming cyanobacterium Trichodesmium.

E. Carpenter, D. Capone, S. Hawser, 1991, Toxicon : official journal of the International Society on Toxinology.

Evaluation of Assay Methods for the Determination of Cyanobacterial Hepatotoxicity

L. Lawton, K. Beattie, G. Codd, 1994 .

Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro.

S. Hawser, M. Borgonovi, A. Markus, 1999, The Journal of antibiotics.

Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class

I. Morrissey, R. Montelaro, P. Ghahramani, 2022, PloS one.

Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum β-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)

F. Baquero, R. Cantón, D. Hoban, 2010, Antimicrobial Agents and Chemotherapy.

Activity of iclaprim against Legionella pneumophila.

I. Morrissey, S. Hawser, 2007, The Journal of antimicrobial chemotherapy.

Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections.

I. Morrissey, K. Keedy, S. Hawser, 2017, International journal of antimicrobial agents.

Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections

P. Hadváry, D. Krievins, S. Hawser, 2009, Antimicrobial Agents and Chemotherapy.

In vitro susceptibility and distribution of beta-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011.

K. Kazmierczak, M. Hackel, D. Hoban, 2014, Diagnostic microbiology and infectious disease.

The Toxicity of Trichodesmium Blooms from Caribbean Waters

G. Codd, S. Hawser, 1992 .

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

M. Motyl, J. Karlowsky, D. Sahm, 2019, The Journal of antimicrobial chemotherapy.

Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

D. Paterson, P. Hsueh, D. Hoban, 2010, International journal of antimicrobial agents.

Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)

D. Hoban, S. Hawser, S. Bouchillon, 2010, Antimicrobial Agents and Chemotherapy.

Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.

D. Hoban, S. Hawser, S. Bouchillon, 2010, Diagnostic microbiology and infectious disease.

Mulundocandin, an Echinocandin‐Like Lipopeptide Antifungal Agent: Biological Activities in vitro.

S. Hawser, M. Borgonovi, A. Markus, 1999 .

Spectrophotometric determination of the morphogenetic transformation by synchronous Candida albicans: effects of antifungal agents.

S. Hawser, K. Islam, 1996, The Journal of antimicrobial chemotherapy.

Binding of Candida albicans to Immobilized Amino Acids and Bovine Serum Albumin

S. Hawser, K. Islam, 1998, Infection and Immunity.

Adhesion of different Candida spp. to plastic: XTT formazan determinations.

S. Hawser, 1996, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

The effects of antifungal agents on the morphogenetic transformation by Candida albicans in vitro.

M. Francolini, S. Hawser, K. Islam, 1996, The Journal of antimicrobial chemotherapy.

Effect of antifungal agents on the binding of Candida albicans to immobilized amino acids and bovine serum albumin.

S. Hawser, K. Islam, 1999, The Journal of antimicrobial chemotherapy.

HAWSER AND DOUGLAS from leukemic patients with line infections or patients with infected aortic grafts at Crosshouse

L. J. Douglas, S. Hawser, L. Douglas, 2022 .

Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Candida albicans.

S. Hawser, K. Islam, 1999, The Journal of antimicrobial chemotherapy.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

K. Kazmierczak, S. Magnet, M. Motyl, 2018, The Journal of antimicrobial chemotherapy.

Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010.

L. Nicolle, D. Hoban, S. Hawser, 2011, Diagnostic microbiology and infectious disease.

Using Nucleic Acid Microarrays To Perform Molecular Epidemiology and Detect Novel (cid:1) -Lactamases: a Snapshot of Extended-Spectrum (cid:1) -Lactamases throughout the World

A. Hujer, M. Hackel, D. Hoban, 2012 .

Comparisons of the susceptibilities of planktonic and adherent Candida albicans to antifungal agents: a modified XTT tetrazolium assay using synchronised C. albicans cells.

S. Hawser, 1996, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

Dissemination of NDM Metallo-β-Lactamase Genes among Clinical Isolates of Enterobacteriaceae Collected during the SMART Global Surveillance Study from 2008 to 2012

K. Kazmierczak, M. Hackel, D. Hoban, 2014, Antimicrobial Agents and Chemotherapy.

3874 H1 and H3, novel antifungal heptaene antibiotics produced by Streptomyces sp. HAG 003874.

M. Kurz, S. Hawser, W. Aretz, 1998, The Journal of antibiotics.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

M. Hackel, D. Hoban, D. Goff, 2014, The Journal of infection.

Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.

D. Paterson, R. Cantón, D. Hoban, 2013, International journal of antimicrobial agents.

Changes in internal and external pH accompanying growth of Candida albicans: studies of non-dimorphic variants

N. Gow, S. Hawser, E. Stewart, 2004, Archives of Microbiology.

Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).

M. Hackel, R. Cantón, D. Hoban, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Dihydrofolate reductase inhibitors as antibacterial agents.

S. Lociuro, S. Hawser, Stephen Hawser, 2006, Biochemical pharmacology.

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.

S. Hawser, P. Schneider, K. Islam, 2003, Bioorganic & medicinal chemistry letters.

In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action.

S. Lociuro, S. Hawser, A. Bernardi, 2007, The Journal of antimicrobial chemotherapy.

Aspirochlorine: a highly selective and potent inhibitor of fungal protein synthesis.

S. Hawser, F. Monti, F. Ripamonti, 1999, The Journal of antibiotics.

Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men.

J. Andrews, D. Honeybourne, S. Hawser, 2007, The Journal of antimicrobial chemotherapy.

Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics

P. Roncada, Abishek Kumar, Bruno Tilocca, 2022, Antibiotics.

Antibacterial drug discovery and development--SRI's 11th Annual Summit.

S. Hawser, 2006, IDrugs : the investigational drugs journal.

Activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from respiratory tract sources.

S. Hawser, 2010, International journal of antimicrobial agents.

Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.

D. Paterson, P. Hsueh, D. Hoban, 2011, The Journal of infection.

Efficacy of Iclaprim against Wild-Type and Thymidine Kinase-Deficient Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Fibrin Clot Model

A. Haldimann, S. Lociuro, S. Hawser, 2009, Antimicrobial Agents and Chemotherapy.

Efﬁcacy of Iclaprim against Wild-Type and Thymidine Kinase-Deﬁcient Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Fibrin Clot Model (cid:1)

A. Haldimann, S. Lociuro, S. Hawser, 2009 .

Deficient Methicillin-Resistant Staphylococcus aureus in an

A. Haldimann, S. Lociuro, S. Hawser, 2009 .

Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.

D. Hoban, S. Hawser, S. Bouchillon, 2011, International journal of antimicrobial agents.

Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.

I. Morrissey, M. Hackel, D. Hoban, 2014, Journal of medical microbiology.

Epidemiologic trends, occurrence of extended-spectrum beta-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: analysis of global trend data from 2002-2007 from the SMART study.

D. Hoban, S. Hawser, S. Bouchillon, 2010, Surgical infections.

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.

M. Motyl, J. Karlowsky, D. Sahm, 2023, Journal of medical microbiology.

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20

M. Motyl, J. Karlowsky, D. Sahm, 2022, JAC-antimicrobial resistance.

Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007

D. Paterson, P. Hsueh, D. Hoban, 2009, Antimicrobial Agents and Chemotherapy.

In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015

I. Morrissey, S. Magnet, P. Knechtle, 2019, Antimicrobial Agents and Chemotherapy.

Fluoroquinolone Resistance Among Gram-Negative Urinary Tract Pathogens: Global Smart Program Results, 2009-2010

D. Hoban, S. Hawser, S. Bouchillon, 2012, The open microbiology journal.

Etiology, Extended-spectrum &bgr;-lactamase Rates and Antimicrobial Susceptibility of Gram-negative Bacilli Causing Intra-abdominal Infections in Patients in General Pediatric and Pediatric Intensive Care Units—Global Data From The Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010

M. Hackel, D. Hoban, S. Hawser, 2013, The Pediatric infectious disease journal.

In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study.

D. Hoban, S. Hawser, S. Bouchillon, 2009, International Journal of Antimicrobial Agents.

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010.

M. Hackel, D. Hoban, S. Hawser, 2013, Diagnostic microbiology and infectious disease.

Using Nucleic Acid Microarrays To Perform Molecular Epidemiology and Detect Novel β-Lactamases: a Snapshot of Extended-Spectrum β-Lactamases throughout the World

R. Bonomo, A. Hujer, M. Hackel, 2012, Journal of Clinical Microbiology.

Antimicrobial susceptibility of intra-abdominal Gram-negative bacilli from Europe: SMART Europe 2008

Y. Carmeli, D. Hoban, P. Hawkey, 2011, European Journal of Clinical Microbiology & Infectious Diseases.

Diagnostic Microbiology and Infectious Disease

K. Kazmierczak, M. Hackel, D. Hoban, 2014 .

Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008.

D. Hoban, S. Hawser, S. Bouchillon, 2010, Journal of medical microbiology.

M. Hackel, E. Kim, S. Hawser, 2012, International journal of antimicrobial agents.

Susceptibility of Klebsiella pneumoniae Isolates from Intra-Abdominal Infections and Molecular Characterization of Ertapenem-Resistant Isolates

N. Woodford, D. Livermore, M. Hackel, 2011, Antimicrobial Agents and Chemotherapy.

Epidemiology and Detect Novel β-Lactamases: a Snapshot of ESBLs

R. Bonomo, A. Hujer, M. Hackel, 2012 .

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020

M. Motyl, D. Sahm, S. Hawser, 2023, European Journal of Clinical Microbiology & Infectious Diseases.

In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.

M. Motyl, J. Karlowsky, D. Sahm, 2020, Journal of medical microbiology.

In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study

D. Sahm, S. Hawser, C. Gemmell, 2017, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.

C. Charrier, S. Hawser, David B. Huang, 2020, Diagnostic microbiology and infectious disease.

Comparative evaluation of iclaprim potency and bactericidal activity tested against enterococci: Results from the International Study of Iclaprim Susceptibility (ISIS)

P. Rhomberg, S. Hawser, H. Sader, 2007 .

Antimicrobial activity of a novel dihydrofolate reductase, iclaprim, tested against clinical strains of Enterobacteriaceae: results from the International Study of Iclaprim Susceptibility (ISIS)

S. Hawser, H. Sader, K. Islam, 2007 .

In vitro activity of tigecycline against carbapenemase-producing Acinetobacter baumannii.

P. Higgins, M. Hackel, H. Seifert, 2010, International journal of antimicrobial agents.

In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates.

J. Karlowsky, K. Hamed, S. Hawser, 2019, Diagnostic microbiology and infectious disease.

Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).

S. Hawser, 2010, The Journal of infection.

In Vitro Activity of a Novel Diaminopyrimidine Compound, Iclaprim, against Chlamydia trachomatis and C. pneumoniae

S. Kohlhoff, S. Hawser, M. Hammerschlag, 2004, Antimicrobial Agents and Chemotherapy.

Effect of human plasma on the antimicrobial activity of iclaprim in vitro.

S. Lociuro, S. Hawser, H. Laue, 2007, The Journal of antimicrobial chemotherapy.

Activity of iclaprim against clinical isolates of Streptococcus pyogenes and Streptococcus agalactiae.

I. Morrissey, S. Hawser, K. Maher, 2008, The Journal of antimicrobial chemotherapy.

In Vitro Bactericidal Activity of Iclaprim in Human Plasma

S. Lociuro, S. Hawser, H. Laue, 2009, Antimicrobial Agents and Chemotherapy.

Infections in Complicated Skin and Skin Structure Efficacy and Safety of Intravenous Iclaprim Multicenter , Randomized Study of the

P. Hadváry, D. Krievins, S. Hawser, 2009 .

Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe

S. Hawser, 2010, European Journal of Clinical Microbiology & Infectious Diseases.

Activity of tigecycline against recent European clinical isolates of Clostridium difficile.

S. Hawser, 2010, International journal of antimicrobial agents.

P476 Monitoring antifungal resistance in a global collection of Candida spp. surveillance isolates, including C. auris—analysis of resistance in antifungals (ARIA) 2020 study

S. Hawser, T. Mathur, N. Kothari, 2022, Medical Mycology.

Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.

I. Morrissey, P. Knechtle, S. Hawser, 2021, Journal of global antimicrobial resistance.

Susceptibility of Ceftobiprole against Gram-positive and Gram-negative Clinical Isolates from 2019 from different European territories.

S. Hawser, Nowel Redder, Noelle Jemmely, 2022, Journal of global antimicrobial resistance.

Production of extracellular matrix by Candida albicans biofilms.

G. Baillie, L. J. Douglas, S. Hawser, 1998, Journal of medical microbiology.

Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011

I. Morrissey, M. Hackel, D. Hoban, 2015, Journal of chemotherapy.

D. Hoban, S. Hawser, S. Bouchillon, 2011, Journal of chemotherapy.

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

P. Savoia, S. Hawser, L. Ferrari, 2022, Antibiotics.

In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016.

S. Hawser, H. Sader, David B. Huang, 2019, Journal of global antimicrobial resistance.

Efficacy Evaluation of Iclaprim in a Neutropenic Rat Lung Infection Model with Methicillin-Resistant Staphylococcus aureus Entrapped in Alginate Microspheres

I. Morrissey, S. Hawser, David B. Huang, 2017, European Journal of Clinical Microbiology & Infectious Diseases.

This is a repository copy of Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate

I. Morrissey, M. Wilcox, S. Hawser, 2018 .

Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.

Po-Ren Hsueh, P. Hsueh, D. Hoban, 2010, International journal of antimicrobial agents.

In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia

M. Pottier, E. Dei‐Cas, N. Gantois, 2018, European Journal of Clinical Microbiology & Infectious Diseases.

Global monitoring of cross-resistance between tigecycline and minocycline, 2004-2009.

S. Hawser, 2010, The Journal of infection.

Anidulafungin (Eli Lilly & Co).

S. Hawser, 1999, IDrugs : the investigational drugs journal.

Resistance Trends ( SMART ) Study for Monitoring Antimicrobial Infections in Europe : Results of the 2008 Hospital-Associated Intra-Abdominal-Lactamases in Community-and β with Extended-Spectrum pneumoniae Klebsiella and Escherichia coli of Incidence and Antimicrobial Susceptibility

F. Baquero, R. Cantón, D. Hoban, 2010 .

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

M. Hackel, D. Hoban, S. Hawser, 2013, Surgical infections.

Susceptibility of global intra-abdominal Enterobacteriaceae isolates to tigecycline (TEST 2007-2010).

D. Hoban, S. Hawser, S. Bouchillon, 2012, The Journal of infection.

Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).

S. Hawser, 2011, International journal of antimicrobial agents.

Activity of ertapenem and comparators against recent clinical isolates from intra-abdominal abscesses (SMART 2009).

S. Hawser, 2011, The Journal of infection.

D. Paterson, P. Hsueh, D. Hoban, 2010, International journal of antimicrobial agents.

Diagnostic Microbiology and Infectious Disease

K. Kazmierczak, M. Hackel, D. Hoban, 2014 .

Efficacy of Iclaprim against Wild-Type and Thymidine Kinase-Deficient Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Fibrin Clot Model

A. Haldimann, S. Lociuro, S. Hawser, 2009, Antimicrobial Agents and Chemotherapy.

Antistreptococcal Activity of AR-709 Compared to That of Other Agents

S. Lociuro, S. Hawser, L. Ednie, 2008, Antimicrobial Agents and Chemotherapy.

Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole

S. Hawser, 2010 .

In Vitro Activity of Finafloxacin against Panels of Respiratory Pathogens

A. Vente, S. Hawser, C. Bentley, 2023, Antibiotics.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

M. Hackel, D. Hoban, S. Hawser, 2013, Surgical infections.

2131. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China

S. Hawser, C. Zampaloni, N. Kothari, 2023, Open Forum Infectious Diseases.

Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections

P. Hadváry, D. Krievins, S. Hawser, 2009, Antimicrobial Agents and Chemotherapy.